Business Context and Reporting Period
This Form 8-K Current Report was filed by Syndax Pharmaceuticals, Inc. on October 4, 2021. The report discloses a significant change in executive leadership regarding the company's financial officers.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly an event report regarding personnel changes.
Material Changes
- Resignation of CFO: Daphne Karydas resigned as Chief Financial Officer, Treasurer, Principal Financial Officer, and Principal Accounting Officer, effective October 22, 2021.
- Reason for Departure: Ms. Karydas is leaving to pursue another opportunity. The filing explicitly states the resignation is not due to any disagreement with the Company regarding operations, policies, or practices.
- Transition Plan: Ms. Karydas will remain with the Company through the end of the year to assist with the transition.
- Interim Appointment: Alexander Nolte, Vice President and Chief Accounting Officer, was appointed as the interim Principal Financial Officer and Principal Accounting Officer effective upon Ms. Karydas's departure.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. The primary risk disclosed is the temporary absence of a permanent Chief Financial Officer while the Company conducts a search for a replacement.
Investor Verification Checklist
- Verify the effective date of the CFO resignation (October 22, 2021).
- Confirm the background and tenure of the interim CFO, Alexander Nolte, within the company.
- Monitor future filings for the appointment of a permanent Chief Financial Officer.
- Review the company's most recent 10-Q or 10-K for actual financial metrics, as this 8-K does not provide them.